- Trials with a EudraCT protocol (28)
 - Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
 
		
	   		
	   		    
                    
                   	
                   	    28 result(s) found for: Magnetic resonance elastography.
                    
                
			
   			
		
		Displaying page 1 of 2.
	
	
	| EudraCT Number: 2011-005846-36 | Sponsor Protocol Number: HGKKRWPHD | Start Date*: 2012-07-31 | ||||||||||||||||||||||||||||||||||||
| Sponsor Name:Gastroenterology MIDT | ||||||||||||||||||||||||||||||||||||||
| Full Title: Safe evaluation of obstructive crohns disease using bloodflow Time-intensity curves and Elastography correlated to Neutrocytes and collagen counts and biomechanical properties Obtained in Stenotic ... | ||||||||||||||||||||||||||||||||||||||
| Medical condition: Crohns Disease undergoing elective surgery for intestinal stenosis. | ||||||||||||||||||||||||||||||||||||||
					
						
							
  | 
			||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
| Trial protocol: DK (Completed) | ||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2016-002496-10 | Sponsor Protocol Number: GS-US-402-1852 | Start Date*: 2017-02-21 | |||||||||||
| Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
| Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects with Nonalcoholic Steatohepatitis (NASH) | |||||||||||||
| Medical condition: Nonalcoholic steatohepatitis (NASH) | |||||||||||||
					
						
							
  | 
			|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: AT (Completed) GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2016-002442-23 | Sponsor Protocol Number: GS-US-428-4025 | Start Date*: 2017-01-09 | |||||||||||
| Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
| Full Title: A Phase 2, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects with Primary Sclerosing Cholangitis Without Cirrhosis | |||||||||||||
| Medical condition: Primary Sclerosing Cholangitis | |||||||||||||
					
						
							
  | 
			|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) AT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2016-004823-21 | Sponsor Protocol Number: PBI-4050-CT-9-10 | Start Date*: 2017-10-25 | |||||||||||
| Sponsor Name:Prometic Biosciences Inc. | |||||||||||||
| Full Title: An Open-Label Rollover Study of PBI-4050 in Subjects with Alström Syndrome | |||||||||||||
| Medical condition: Alström Syndrome | |||||||||||||
					
						
							
  | 
			|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2020-006023-33 | Sponsor Protocol Number: SIMFIB | Start Date*: 2021-10-26 | ||||||||||||||||
| Sponsor Name:Institut d’Investigacions Biomèdiques August Pi i Sunyer | ||||||||||||||||||
| Full Title: Efficacy of simvastatin reducing liver fibrosis in patients with advanced fibrosis due to alcohol: a randomized, double-blind, placebo-controlled clinical trial. | ||||||||||||||||||
| Medical condition: reduction of liver fibrosis in patients with advanced fibrosis due to alcohol | ||||||||||||||||||
					
						
							
  | 
			||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: ES (Ongoing) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2018-004431-79 | Sponsor Protocol Number: CC-90001-NASH-001 | Start Date*: 2019-11-15 | 
| Sponsor Name:Celgene Corporation | ||
| Full Title: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, DOSEFINDING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-90001 IN SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) AND LIVE... | ||
| Medical condition: Confirmed diagnosis of NASH and Stage 3 or Stage 4 fibrosis based upon the NASH Clinical Research Network (CRN) Histologic Scoring System and a nonalcoholic fatty liver disease (NAFLD) Activity Sco... | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: GB (GB - no longer in EU/EEA) FR (Prematurely Ended) ES (Ongoing) PL (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2019-004999-19 | Sponsor Protocol Number: 191001 | Start Date*: 2020-06-16 | |||||||||||
| Sponsor Name:Department of infectious diseases, Hvidovre Hospital | |||||||||||||
| Full Title: Changes in weight, body composition and metabolic parameters after switch to dolutegravir/lamuvidine compared to continued treatment with dolutegravir/abacavir/lamuvidine for virologically suppress... | |||||||||||||
| Medical condition: Human immunodeficiency viruses (HIV) | |||||||||||||
					
						
							
  | 
			|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DK (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2015-000359-26 | Sponsor Protocol Number: ESTEVE-SANF-201 | Start Date*: 2016-04-29 | 
| Sponsor Name:Laboratorios del Dr. Esteve, S.A. | ||
| Full Title: Phase I/II safety, tolerability and initial efficacy study of adeno-associated viral vector serotype 9 containing human sulfamidase gene after intracerebroventricular administration to patients wit... | ||
| Medical condition: Mucopolysaccharidosis type IIIA (Sanfilippo A syndrome) is an inherited lysosomal storage disease caused by a specific lysosomal enzyme deficiency that leads to intracellular accumulation of the ... | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
| Trial protocol: ES (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2017-004365-27 | Sponsor Protocol Number: EDP-305-101 | Start Date*: 2018-12-17 | |||||||||||
| Sponsor Name:Enanta Pharmaceuticals Inc. | |||||||||||||
| Full Title: A Phase 2 Dose Ranging, Randomized, Double Blind, and Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects with Non-Alcoholic Steatohep... | |||||||||||||
| Medical condition: Non-alcoholic Steatohepatitis (NASH) | |||||||||||||
					
						
							
  | 
			|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Completed) GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2017-003430-85 | Sponsor Protocol Number: OBERAL | Start Date*: 2017-11-29 | 
| Sponsor Name:Helsinki University Hospital | ||
| Full Title: A randomized, open, parallel design study to evaluate the effect on liver fat, adipose tissue and metabolic parameters when switching a protease inhibitor or efavirenz to once daily raltegravir in ... | ||
| Medical condition: Study subjects are HIV infected patients with BMI>25kg/m2 and who have at least one metabolic syndrome component or a fatty liver disease. | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: FI (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2019-003876-38 | Sponsor Protocol Number: EDP305-102 | Start Date*: 2020-08-19 | |||||||||||
| Sponsor Name:Enanta Pharmaceuticals Inc. | |||||||||||||
| Full Title: A Phase 2b Randomized, Double Blind, Placebo-Controlled, Multicenter Study Evaluating Safety and Efficacy of EDP-305 in Subjects with Liver-Biopsy Proven Non-Alcoholic Steatohepatitis (NASH) (ARGON-2) | |||||||||||||
| Medical condition: Non-alcoholic Steatohepatitis (NASH) | |||||||||||||
					
						
							
  | 
			|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Prematurely Ended) GB (GB - no longer in EU/EEA) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2016-002443-42 | Sponsor Protocol Number: GS-US-427-4024 | Start Date*: 2017-01-09 | |||||||||||
| Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
| Full Title: A Phase 2, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects with Primary Biliary Cholangitis Without Cirrhosis | |||||||||||||
| Medical condition: Primary Biliary Cholangitis | |||||||||||||
					
						
							
  | 
			|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) AT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2020-001428-33 | Sponsor Protocol Number: PLN-74809-PSC-203 | Start Date*: 2020-11-05 | |||||||||||
| Sponsor Name:Pliant Therapeutics, Inc | |||||||||||||
| Full Title: A randomized, double-blind, dose-ranging, placebo-controlled, Phase 2a evaluation of the safety, tolerability, and pharmacokinetics of PLN-74809 in participants with primary sclerosing cholangitis ... | |||||||||||||
| Medical condition: Primary sclerosing cholangitis (PSC) | |||||||||||||
					
						
							
  | 
			|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) AT (Completed) DE (Completed) BE (Completed) FR (Completed) NL (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2014-003942-28 | Sponsor Protocol Number: MLN0002-3023 | Start Date*: 2016-05-29 | |||||||||||||||||||||
| Sponsor Name:Takeda Development Centre Europe, Ltd. | |||||||||||||||||||||||
| Full Title: Randomized, Global, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Vedolizumab IV for the Treatment of Primary Sclerosing Cholangitis, With Underlying... | |||||||||||||||||||||||
| Medical condition: Primary Sclerosing Cholangitis (PSC) Inflammatory Bowel Disease (IBD) | |||||||||||||||||||||||
					
						
							
  | 
			|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: ES (Completed) BE (Prematurely Ended) GB (Completed) HU (Prematurely Ended) SE (Prematurely Ended) DE (Prematurely Ended) CZ (Completed) AT (Prematurely Ended) PL (Prematurely Ended) FR (Completed) IT (Prematurely Ended) | |||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||
| EudraCT Number: 2020-005187-63 | Sponsor Protocol Number: FM101-CTP2-001 | Start Date*: 2021-04-14 | ||||||||||||||||
| Sponsor Name:Future Medicine Co., Ltd. | ||||||||||||||||||
| Full Title: A Randomized Phase 2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of FM101 in Adults with Nonalcoholic Fatty Liver Disease (NAFLD) or Nonalcoholic Steatohepatitis (NASH) | ||||||||||||||||||
| Medical condition: Nonalcoholic Fatty Liver Disease (NAFLD) or Nonalcoholic Steatohepatitis (NASH) | ||||||||||||||||||
					
						
							
  | 
			||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: HU (Prematurely Ended) ES (Prematurely Ended) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2013-004200-19 | Sponsor Protocol Number: PRICKLE | Start Date*: 2014-06-13 | |||||||||||
| Sponsor Name:Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge | |||||||||||||
| Full Title: Pancreatic Resectability in Cancers with Known Limited Extension (PRICKLE) - A single-centre phase 2a study of Gemcitabine plus Nab-paclitaxel for borderline unresectable locally advanced pancreati... | |||||||||||||
| Medical condition: Locally advanced pancreatic cancer | |||||||||||||
					
						
							
  | 
			|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2017-001611-37 | Sponsor Protocol Number: T2F12017 | Start Date*: 2019-02-27 | 
| Sponsor Name:Medical University Vienna, Gender Medicine Unit, Div. of Endocrinology, Dep of Medicine III | ||
| Full Title: A 52 week prospective randomized controlled study to investigate the effect of intramuscular testosterone undecanoate supplementation vs placebo on intrahepatic fat content in overweight/obese men ... | ||
| Medical condition: hypogonadism, T2DM, prediabetes, overweight, obesity | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male | |
| Trial protocol: AT (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2022-000875-37 | Sponsor Protocol Number: VanC-IT | Start Date*: 2022-11-03 | |||||||||||
| Sponsor Name:UNIVERSITÀ DEGLI STUDI MILANO BICOCCA | |||||||||||||
| Full Title: A Prospective, Randomized, Placebo-controlled Clinical Trial of oral vancomycin in adults and young adults (15-17 years old) affected by Primary Sclerosing Cholangitis with or without Inflammatory ... | |||||||||||||
| Medical condition: Primary Sclerosing Cholangitis | |||||||||||||
					
						
							
  | 
			|||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2012-002488-88 | Sponsor Protocol Number: GS-US-321-0105 | Start Date*: 2013-07-29 | |||||||||||
| Sponsor Name:Gilead Sciences Inc | |||||||||||||
| Full Title: A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase-Like 2 (LOXL2), in Subjects w... | |||||||||||||
| Medical condition: Advanced Liver Fibrosis Secondary to Non-Alcoholic Steatohepatitis (NASH) | |||||||||||||
					
						
							
  | 
			|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) DE (Prematurely Ended) GB (Prematurely Ended) ES (Completed) BE (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2012-002473-61 | Sponsor Protocol Number: GS-US-321-0102 | Start Date*: 2013-05-08 | |||||||||||
| Sponsor Name:Gilead Sciences Inc | |||||||||||||
| Full Title: A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase Like 2 (LOXL2) in Subjects wi... | |||||||||||||
| Medical condition: Primary Sclerosing Cholangitis (PSC) | |||||||||||||
					
						
							
  | 
			|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) GB (Completed) SE (Completed) IT (Completed) DK (Completed) ES (Completed) BE (Completed) NL (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
			Subscribe to this Search
To subscribe to the RSS feed for this search click here
			.
			This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
		
			
To subscribe to the RSS feed for this search click here
			.
			This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
		| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
    	Query did not match any studies.